Clinical Trial Update: A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the PET imaging agent [89]Zr-Df-IAb2M for high-risk prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• [89]Zr-Df-IAb2M

Snippet

Sponsor: ImaginAb, Inc. | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN